Home > Healthcare > Medical Devices > Diagnostic Devices > Arachnoid Cysts Treatment Market

Arachnoid Cysts Treatment Market Analysis

  • Report ID: GMI9110
  • Published Date: Apr 2024
  • Report Format: PDF

Arachnoid Cysts Treatment Market Analysis

Based on the type, the global market is classified into intracranial arachnoid cysts and spinal arachnoid cysts. The intracranial arachnoid cysts segment dominated the market with revenue of USD 739.8 million in 2023.
 

  • The growing awareness among healthcare professionals and the patient about intracranial arachnoid cysts leads to more frequent detection and diagnosis of the disease condition, driving demand for treatment options.
     
  • Moreover, the rise in technological advancements in neuroimaging techniques such as MRI and CT scans enable more accurate and early detection of intracranial arachnoid cysts, contributing to market growth by increasing the number of identified cases, and hence propel the growth of the market.
     
Arachnoid Cysts Treatment Market, By Diagnosis (2023)

Based on the diagnosis, the global arachnoid cysts treatment market is classified into CT scan, MRI scan, prenatal ultrasound, and other diagnosis. The CT scan segment dominated the market with market share of 54.3% in 2023.
 

  • CT scans play a crucial role in the diagnosis, treatment planning, and monitoring of arachnoid cysts. The various advantages offered by CT scan such as accuracy in diagnosis, accessibility and availability, speed and efficiency and improved image quality as compared to other diagnosis devices drive the growth of CT scans in the market.
     
  • Moreover, compared to MRI, CT scans are generally more cost-effective and accessible, making them a preferred imaging modality in resource-constrained healthcare settings. The cost-effectiveness of CT scans contributes to the widespread use in the evaluation and management of arachnoid cysts.
     

Based on treatment type, the arachnoid cysts treatment market is classified into endoscopic cysts fenestration, fenestration, and permanent drainage system surgery. The endoscopic cysts fenestration segment is expected to exhibit 6.2% CAGR between 2024 - 2032.
 

  • Endoscopic cyst fenestration is increasingly recognized as an effective treatment option for arachnoid cysts, particularly in cases where surgical intervention is necessary. The rise in the demand for minimally invasive surgical procedures and shorter hospital stays are the major factors that contribute to the growth of the endoscopic cysts fenestration market.
     
  • Moreover, the ongoing advancements in endoscopic instrumentation, surgical techniques, and imaging modalities have further improved the safety and efficacy of cyst fenestration procedures. Thus, this will increase the demand for endoscopic cysts fenestration treatment type, that boost the growth of the market, during the forecast period.
     

Based on end-use, the arachnoid cysts treatment market is classified into hospitals, ambulatory surgical centers, and other end-users. The hospitals segment is expected to exhibit 6.1% CAGR between 2024 - 2032.
 

  • Hospitals play a central role in providing comprehensive care to patients with arachnoid cysts, contributing to market growth. The rising incidence and prevalence of arachnoid cysts worldwide drive demand for healthcare services, including diagnosis, treatment, and management.
     
  • Moreover, hospitals often have access to advanced diagnostic and imaging technologies, such as MRI, CT scans, and neuroimaging modalities, which are essential for accurate diagnosis and treatment planning of arachnoid cysts. The availability of these facilities attracts patients seeking specialized care for the disease condition.

     
North America Arachnoid Cysts Treatment Market, 2021 – 2032 (USD Million)

In 2023, North America secured a substantial market share of 44.1% in the global arachnoid cysts treatment market and is expected to dominate throughout the forecast period.
 

  • North America has one of the highest healthcare expenditures globally, driven by factors such as increasing healthcare demand, technological advancements, and aging demographics.
     
  • Higher healthcare spending translates into greater investment in diagnostic, therapeutic, and surgical interventions for conditions like arachnoid cysts, stimulating market growth.
     
  • In addition, stringent regulatory oversight in North America ensures the safety, efficacy, and quality of medical devices, pharmaceuticals, and healthcare services. Compliance with regulatory requirements instills confidence among patients, healthcare providers, and investors, fostering innovation and growth in the market.
     

The arachnoid cysts treatment market in U.S. is expected to exhibit 5.9% CAGR between 2024 - 2032.
 

  • The presence of advanced healthcare infrastructure in U.S. with advanced diagnostic and treatment technologies for arachnoid cysts stimulating the market growth.
     
  • Moreover, the increase in the diagnostic rate of arachnoid cysts owing to rise in awareness among healthcare professionals and patients drive patient engagement and demand for treatment services, fueling market growth.
     

Germany to experience the highest growth rate in the market, outstripping other countries in Europe in the assessment period.
 

  • The presence of prominent industry players, along with increase in research and development activities, leading to the development of advanced diagnostic tools, surgical techniques, and medical devices for the treatment of arachnoid cysts. Thus, the rise in technological innovations improves treatment outcomes and stimulates market growth.
     
  • Moreover, health insurance coverage for the treatment of a wider range of options for arachnoid cysts, driving market growth as adequate insurance coverage reduces financial barriers to treatment.
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Arachnoid cysts treatment market size was USD 1.3 billion in 2023 and is expected to register 5.7% CAGR from 2024-2032 owing to the rising incidence and prevalence of arachnoid cysts attributed to factors such as improved diagnostic techniques and an aging population worldwide.

The intracranial arachnoid cysts segment recorded USD 739.8 million in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to growing awareness among healthcare professionals and the patient about this disease.

North America arachnoid cysts treatment industry held 44.1% share in 2023 and is expected to register a commendable CAGR from 2024-2032 due to increasing healthcare demand, technological advancements, and aging demographics in the region.

Aesculap Inc., B. Braun Melsungen AG, FUJIFILM Sonosite Inc., GE Healthcare, Integra Life Sciences, Karl Storz, Koninklijke Philips N.V, Medtronic PLC, Siemens Healthineers, Sophysa, and Spiegelberg GmbH & Co., are some of the major arachnoid cysts treatment companies worldwide.

Arachnoid Cysts Treatment Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 10
  • Tables & Figures: 266
  • Countries covered: 22
  • Pages: 161
 Download Free Sample